US 12,478,585 B2
Micelles and vesicles for the delivery of glycopeptides
Robin L. Polt, Tucson, AZ (US); Dillon Hanrahan, Tucson, AZ (US); Lajos Z. Szabo, Tucson, AZ (US); Michael L Heien, Tucson, AZ (US); and Chenxi Liu, Tucson, AZ (US)
Assigned to ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, Tucson, AZ (US)
Filed by ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, Tucson, AZ (US)
Filed on Nov. 21, 2022, as Appl. No. 18/057,665.
Application 18/057,665 is a continuation in part of application No. 16/637,671, granted, now 11,504,325, previously published as PCT/US2018/046078, filed on Aug. 9, 2018.
Claims priority of provisional application 62/543,362, filed on Aug. 9, 2017.
Prior Publication US 2023/0104480 A1, Apr. 6, 2023
Int. Cl. A61K 9/12 (2006.01); A61K 9/1272 (2025.01); A61K 38/07 (2006.01); A61K 38/08 (2019.01); A61K 38/095 (2019.01); A61K 38/18 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01)
CPC A61K 9/1272 (2013.01) [A61K 38/07 (2013.01); A61K 38/08 (2013.01); A61K 38/085 (2013.01); A61K 38/095 (2019.01); A61K 38/1866 (2013.01); A61K 47/12 (2013.01); A61K 47/18 (2013.01); A61K 47/186 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A supramolecular assembly comprising:
a. at least one glycopeptide; and
b. at least one amphipathic molecule;
wherein said supramolecular assembly is capable of delivering the at least one glycopeptide to a cell; and wherein the at least one glycopeptide is a glycosylated angiotensin, glycosylated VEGF peptide fragment, glycosylated oxytocin, glycosylated VIP agonist, or glycosylated PACAP agonist.